Sleep Apnea Worsens Acute HF Outcomes; Testing for It at HF Admission Proposed

October 04, 2013

ORLANDO, FL — Sleep-disordered breathing (SDB) identified during acute decompensated heart failure (ADHF) hospitalization, especially central sleep apnea (CSA), predicted elevated cardiac readmission risk at three and six months and a two-thirds increase in mortality at three years in a prospective cohort study[1,2].

Its authors propose that routine screening and treatment for central or obstructive sleep apnea (OSA) in hospitalized heart-failure patients might be a useful strategy for bringing down ADHF readmission rates and associated late mortality.

Sleep-disordered breathing is one of the most common heart-failure comorbidities, identified in >70% of patients admitted with ADHF, the study's senior author Dr Rami N Khayat (Ohio State University, Columbus) told heartwire here at the Heart Failure Society of America 2013 Scientific Meeting . Although sleep studies aren't typically performed after admissions for HF, he recommends that they be routinely included for patients without a prior diagnosis of SDB "early on in the hospitalization."

Khayat presented the single-center study of 1117 patients admitted for ADHF from 2007 to 2010 with lead author Angela Sow (Ohio State University). All had an LVEF <45% and had never been diagnosed with SDB. Their sleep studies conducted on the second night of admission used type 3 monitors (with a minimum of four physiologic monitoring channels). SDB was defined as an apnea-hypopnea index of >15 events per hour (usually considered moderate apnea).

Features of 1117 Patients With Central or Obstructive Sleep Apnea or No Sleep Disordered Breathing

End points CSA, n=344 OSA, n=525 No SDB, n=248 p
Age (y) 60.3 60.3 54.6 <0.05 vs CSA and OSA
LVEF (%) 23.1 26.3 29.5 <0.05 vs CSA and OSA
BMI 29.4 31.7 29.0 <0.05 vs OSA
LOS (d) 9.5 9.0 7.2 <0.05 vs CSA and OSA

CSA=Central sleep apnea
OSA=obstructive sleep apnea
SDB=sleep disordered breathing
BMI=body-mass index
LOS=hospital length of stay

CSA and OSA showed comparable significant, independent effects on late mortality. Both were independent predictors of six-month cardiac readmission, the risk doubling for CSA, in particular. CSA was an independent predictor of cardiac readmission at one, three, and six months.

Hazard Ratio (95% CI) for Mortality and Rate Ratio (95% CI) for Cardiac Readmission in 1117 Patients With CSA, OSA, or No SDB

Outcome CSA vs No SDB CSA vs OSA OSA vs No SDB
36-mo mortality 1.71 (1.2–2.5), p=0.007 1.03 (0.8–1.3), p=0.81 1.66 (1.1–2.4), p=0.007
1-mo cardiac readmission 1.92 (1.2–3.1), p=0.009 1.29 (0.9–1.8), p=0.14 1.48 (0.9–2.3), p=0.10
3-mo cardiac readmission 1.66 (1.2–2.4), p=0.005 1.33 (1.0–1.7), p=0.03 1.25 (0.9–1.7), p=0.20
6-mo cardiac readmission 1.97 (1.4–2.7), p<0.001 1.42 (1.1–1.8), p=0.004 1.39 (1.0–1.9), p=0.03

Adjusted for age, sex, LVEF, BMI, creatinine, diabetes, type of cardiomyopathy, CAD, chronic kidney disease, discharge SBP <110, hypertension, discharge ACE inhibitors or angiotensin-receptor blocker, discharge beta-blocker, index length of stay, admission Na and hemoglobin.

Khayat acknowledged that SDB in many patients could represent a facet of the acute heart-failure syndrome, rather than a distinct disorder; he said if so, it remains an independent measure of worsened HF "not explained away by LVEF, LV end-diastolic dimensions, natriuretic peptides, or anything else."

He added, "We've done validation studies on a similar [cohort, suggesting that] sleep-disordered breathing doesn't go away or change much after they're discharged."

Neither Khayat nor Sow had disclosures; Khayat has elsewhere disclosed previously consulting for Respicardia and receiving research grants from Respironics.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.